IDirect HealthCheck Oct16

Monthly Update
October 17, 2016
Health Check
Sector View
Positive
India, EMs to support Q2FY17 besides US
Index Performance as on October 14, 2016

Return (%)
Return (%)
1M
3M
YTD
1Y
CNX 500
1.3
8.8
11.4
12.7
Nifty
1.3
6.8
10.5
10.0
NSE Pharma
1.2
10.4
-1.9
-7.7
Stocks Performance
Mcap
Return (%)
Company
1M
3M
YTD
1Y
14-Oct
Sun Pharma.Inds.
-0.6
5.8
-5.0
Lupin
-1.9
6.6
-15.9
-17.8
69689
-13.5 187445
Dr Reddy's Labs
4.7
3.4
1.4
-20.3
52244
Cipla
8.0
24.4
-7.4
-7.4
48323
Aurobindo Pharma
5.6
12.0
-7.8
13.5
47261
Cadila Health.
4.9
24.1
19.5
-1.6
40069
Divi's Lab.
2.3
19.0
15.1
19.0
35287
Torrent Pharma.
4.2
21.6
12.7
13.8
27360
Glenmark Pharma.
4.0
18.1
-2.4
-12.0
25394
Glaxosmit Pharma
-10.0
-20.0
-15.2
-16.1
23806
Biocon
11.6
30.5
82.5
114.9
18911
Apollo Hospitals
-5.8
0.4
-10.5
-3.8
18251
Ajanta Pharma
-0.2
34.1
47.6
35.8
17298
Alembic Pharma
1.1
20.3
-6.2
-5.8
12310
Natco Pharma
-0.8
26.9
10.0
41.2
11094
Jubilant Life
24.1
84.3
52.7
81.3
10007
Wockhardt
11.8
-1.0
-41.7
-35.4
9851
Syngene Int.
13.8
17.9
15.7
49.7
9641
Strides Arcolab
4.6
-5.2
-20.0
-14.1
9211
Pfizer
4.7
5.9
-15.3
-22.4
9140
Ipca Labs.
20.2
-20.3
-22.2
7457
8.1
25.7
1.2
1.1
3051
Unichem Labs.
-2.7
1.1
-1.6
-3.6
Market cap in | crore
Price movement
Oct-15
12000
10000
8000
6000
4000
Jan-16
Apr-16
CNX Pharma
Jul-16
On the regulatory front, Cipla has received an establishment inspection

report (EIR) from the USFDA for its Indore facility indicating formal closure
of the USFDA inspection conducted in July/September, 2015. However, it
has also received four observations from the USFDA for the Goa plant.
Alembic Pharma has also received EIR for its Panelav formulation plant at
Gujarat regarding inspection carried out in March 2016.
On the approvals front, Jubilant Life Sciences received USFDA 505 (b)(2)
approval (new drug application) for nuclear medicine Ruby-Fill (Rubidium
2389 M 82). The product is expected to be launched in Q3FY17. As per
management estimates, the current US market size is US$76 million and has
the potential to grow up to US$250 million annually in the next five years.
15.2
Indoco Remedies
15000
14000
13000
12000
11000
10000
9000
8000
7000
6000
5000
In Q2FY17, the I-direct healthcare universe revenues are expected to grow

~9% YoY to | 38020 crore led by growth in the US and India. Similarly, the
normalised currency impact in most emerging markets (EMs) along with
price hikes in Brazil and launches of new products across EMs are likely to
support overall growth. Venezuela issues, however, would continue to
impact Dr Reddys (DRL) and Glenmark. US sales from the select pack are
expected to grow ~12% to | 10119 crore on the back of 1) rupee
depreciation vis--vis US$ (~3% YoY), 2) exclusivity sales (gGleevec by
Sun, gGlumetza by Lupin) 3) consolidation of acquisitions and 4)
incremental product launches & price hikes (gFortamet by Lupin). However,
increased competition in existing products especially in gAbilify, gNexium
and price erosions elsewhere may partly offset overall US growth. On the
domestic formulations front, despite continued NLEM/FDC issues, growth is
likely to be 10% YoY to | 8244 crore (selected pack) on the back of a
favourable seasonality benefit over and above the volume growth and new
launches. We expect the EBITDA of the I-direct healthcare universe to grow
~9% YoY to | 9772 crore on a higher base. EBITDA margins are likely to
remain strong at ~26% YoY due to a better product mix. Net profit of the Idirect healthcare coverage is expected to grow 11.9% YoY to | 6085 crore.
Higher net profit growth vis--vis EBITDA was on account of lower interest
expenses and taxation.
Oct-16
Nifty (RHS)
Research Analyst
Siddhant Khandekar
siddhant.khandekar@icicisecurities.com
Mitesh Shah
mitesh.sha@icicisecurities.com
ICICI Securities Ltd. | Retail Equity Research
Finally, on the domestic front, the Indian pharmaceutical market (IPM) grew
12.8% in Q2FY17. The growth was mainly driven by volume increase
6.7% followed by new product launches 3.3% and price hikes - 2.8%. On
a MAT basis, IPM growth was at 10.9% YoY to | 103820 crore.
Earnings likely to stabilise; regulatory worries waning
Despite pricing pressure and client consolidation in the US, most players
(barring a few) may manage to maintain growth mainly due to accelerated
new product approvals and market share gains in existing products thereby
neutralising these headwinds. Regarding USFDA issues, Indian players have
moved on and seem better prepared than 12-18 months ago as reflected in
the growing number of EIRs by the USFDA for Indian facilities. Indian
formulations are also likely to do well despite NLEM/FDC issues. Overall, in
the long run, we expect earnings momentum to continue on the back of
incremental product launches in the US and likely positive outcome from
the USFDA re-inspections besides normalising of Indian formulations
growth. We expect healthcare universe revenues, EBITDA and PAT to grow
at a CAGR of 12%, 13% and 16%, respectively, in FY16-18E. The growth is
expected to be steered by US (~13% CAGR over FY16-18E) and Indian
formulations (~14% CAGR over FY16-18E).
Regulatory approvals
Exhibit 1: Summary of USFDA approvals for Sep, 2016
[5
Company
Cipla
Taro Pharma
Glenmark Pharma
Ajanta Pharma
Glenmark Pharma
Aurobindo Pharma
Cipla (Invagen)
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Sun Pharma
Lupin
Drug Name
Darifenacin ER
Naftifine HCL
Lidocaine
Aripiprazole
Diclofenac Sodium
Eszopiclone tablets
Amlodipine Besylate; Valsartan
Darifenacin ER
Ayuna (Ethinyl Estradiol; Levonorgestrel)
Incassia (Norethindrone)
Zoledronic Acid
Memantine Hydrochloride
Memantine Hydrochloride
Company
Lupin
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Drug Name
SILODOSIN
DOLUTEGRAVIR
Abacavir Sulfate;Lamivudine tablets
Tadalafil
Final Approvals
Therapeutic Area
Urinary
Anti-Infective
Dermatology
CNS
Anti-inflammatory
Insomnia
CVS
Urinary
OC
OC
hypercalcemia
CNS
CNS
Tentative Approvals
Therapeutic Area
Urinary
Antiviral
HIV
CVS
Innovator company
APIL
MERZ PHARMS
Astrazeneca
Otsuka
Fougera Pharma
Sepracor
Novartis
APIL
NA
NA
Novartis
Forest Labs
Forest Labs
Generic Version of
ENABLEX ER
NAFTIN
Xylocaine
Abilify
Solaraze
Lunesta
Exforge
ENABLEX ER
NA
NA
Zometa
Namenda
Namenda
Market Size
US$ 85 million
NA
US$ 373 million
NA
US$ 298 million
NA
US$ 123 million
US$ 85 million
NA
NA
NA
US$ 1.22 billion
US$ 1.22 billion
Innovator company
Allergan
ViiV Healthcare
ViiV Healthcare
Eli Lilly
Generic Version of
RAPAFLO
Tivicay
Epzicom
Adcirca
Market Size
NA
NA
NA
NA
CNS: Central Nervous System; CVS: Cardiovascular, GI: Gastro Intestinal, NA: Not available;
Source: USFDA, ICICIdirect.com Research
M&As, demergers, tie-ups and JVs
Syngene purchases assets from Strand Life Sciences

Syngene has purchased the assets of Strand Life Sciences related to
systems biology, Heptox and pharma bioinformatics services. This includes
the target dossier business and rights to NGS data analytics and Sarchitect
platforms, supported by a strong scientific team. Financial details of the deal
were not disclosed.
Sun Pharma signs deal with ICGEB in India to develop dengue vaccine
Sun Pharma has signed a deal with the Delhi unit of the International Centre
for Genetic Engineering and Biotechnology (ICGEB) to develop a dengue
vaccine. This would be the first time a vaccine has been developed entirely
in India for a vector-borne disease.
Cadila goes for collaboration for anti-malaria drug
Cadila and Medicines for Malaria Venture (MMV) have announced a
collaboration to develop the investigational anti-malarial compound,
MMV674253. Cadila will lead the development of the novel compound and
MMV will provide support, including scientific expertise and access to tools
in malaria drug development and delivery.
Lupin, MonoSol Rx announce licensing agreement
Lupin Pharma and MonoSol Rx have entered into a strategic licensing
agreement wherein Lupin would develop multiple paediatric products
utilising MonoSol Rxs proprietary PharmFilm drug delivery technology.
MonoSol Rxs PharmFilm technology is a drug delivery platform that
provides precision dosing in the form of a quick-dissolving, taste-masked
and easy-to-administer dissolvable film.
Price cuts, new launches, recalls, approvals
~100 Medicines removed from NPPA list

~100 medicines, including alzheimer's, diabetes and hypertension have
been removed from the national list of essential medicines (NLEM).
Overruling a previous order by the drug price regulator, the Centre has
allowed firms to hike prices of medicines no longer part of the NLEM.
Lupin recall drugs in the US
Page 2
Lupin Pharma is recalling 3,192 bottles (319,200 tablets) of Escitalopram

(antidepressant) from the US due to incorrect or missing lot and/or expiry
date. As per reports, the recalls fall under a class III category. The drug was
manufactured at Lupins Goa plant.
Sun Pharma recalls drugs in US
Sun Pharma is recalling 31762 bottles of bupropion hydrochloride extended
- release tablets used for treatment of major depressive disorder in the US
due to failed dissolution specifications. This recalls is considered under
class III recall category
Jubilant receives USFDA approval for Ruby-Fill
Through one of its units Jubilant DraxImage Inc. Montreal Canada, Jubilant
Life has received USFDA 505 (b)(2) approval (new drug application) for
Ruby-Fill. Ruby-Fill is used for Positron Emission Tomography (PET)
imaging of the myocardium under rest or pharmacologic stress conditions
to evaluate regional myocardial perfusion in adult patients with suspected
or existing coronary artery disease. The product is expected to be launched
in Q3FY17. The current estimated US market size is US$76 million.
Jubilant receives Australian approval for lyophilised kit
Through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI),
Jubilant Life has received approval from TGA, Australia for lyophilised kit for
the preparation of Technetium 99m Macro-Aggregated Albumin (MAA)
Injection (nuclear medicine). MAA provides accurate scans to assess lung
perfusion and rule out pulmonary embolism with low radiation exposure.
Unichem recalls 368 bottle bottles of Lamotrigine tablets in US
Unichem is recalling 368 bottles of Lamotrigine tablets, used for treating
epilepsy and bipolar disorder in the US due to incorrect imprint debossed
on tablets. This recall has been considered under class III recall category.
Cadila to launch immunosuppressant drug in India
Cadila Healthcare has partnered with Neovii (Switzerland) to launch
Grafalon in India. Grafalon is use to reduce the strength of the bodys
immune system. The drug is extensively used in solid organ transplants and
stem cell transplant. As per the company, the market for transplant-immuno
therapies is estimated at | 483 crore.
Lawsuits, court rulings, settlements, regulatory issues
Cipla gets four observations from USFDA for three plants in Goa
Cipla has got four observations from USFDA for three of its manufacturing
facilities in Goa. As per the management, these observations were
procedural in nature. The company has already responded to the USFDA
Alembic receives EIR for Panelav facility
Alembic Pharma has received an establishment inspection report (EIR) from
USFDA for its Panelav formulation plant at Gujarat for the inspection carried
out in March 2016.
NPPA slashes prices of over 30 essential medicines
The National Pharmaceutical Pricing Authority (NPPA) has slashed prices of
over 30 essential medicines in a move would make several cancer
medicines and antibiotics cheaper. According to the body, prices of some
medicines have been slashed by as much as 55%.
Cipla receives EIR from USFDA for three Indore plants
Cipla has received an EIR from the USFDA for its Indore facility indicating
formal closure of the USFDA inspection conducted in July/September,
2015. US was 15% of total sales in FY16. A majority of the companys US
filings from India are from this facility. Although the financial impact may
not be material, this bodes well for approval continuum in the future.
Page 3
Others
Apollo, Italy's KOS group launch medical rehabilitation hospital

Apollo Hospitals and KOS Group of Italy on Thursday announced the
opening of an exclusive rehabilitation centre for post-operation care to
patients.
Jubilant Life Sciences raises US$300 million via bond
Jubilant has raised US$300 million through issuance of five-year bonds.
Jubilant has successfully completed the pricing of its rated unsecured high
yield bonds (notes) at a yield of 4.875% issued at par for US$300 million
maturing in September 2021. The net proceeds of the notes will be used to
prepay the existing debt of Jubilant Pharma and its subsidiaries, for
upstreaming up to US$50 million to Jubilant Life Sciences for prepayment
of its existing debts and general corporate purposes.
Dr Reddy's forays into Colombian market
Dr Reddy's has announced its entry into the Colombian market with its
portfolio of cancer drugs.
Aurobindo Pharma promoter sells stake to KKR for personal reason
As per media sources, the founders of Aurobindo Pharma have sold 3-4%
stake to the KKR for their personal fund requirement.
Bombay HC orders Sun Pharma to cough up pending wages
The Bombay High Court has rejected a writ petition filed by Sun Pharma
against an order of the Maharashtra Industrial Court asking the company to
pay pending wages of 86 sales representatives. The Federation of Medical
and Sales Representatives Associations of India had filed a lawsuit against
Sun Pharma in June, alleging that the company was engaging in unfair
labour practices after it withheld salary and expenses of the sales
representatives since May.
Page 4
Exhibit 2: Patent litigations (12 months)

[5
Month
Oct-15
Oct-15
Oct-15
Oct-15
Oct-15
Oct-15
Oct-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Dec-15
Dec-15
Dec-15
Dec-15
Dec-15
Dec-15
Jan-16
Jan-16
Feb-16
Feb-16
Feb-16
Mar-16
Mar-16
Apr-16
May-16
Jun-16
Jun-16
Jun-16
Jun-16
Jun-16
Jul-16
Jul-16
Jul-16
Jul-16
Jul-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Sep-16
Sep-16
Sep-16
Sep-16
Sep-16
Sep-16
Sep-16
Sep-16
Innovator
ANDA Filer
Merck
Lupin
Salix Pharmaceuticals, Inc.
Taro Pharma
Takeda Pharma
Aurobindo
Janssen Pharma
Aurobindo
Novartis Pharma
Natco Pharma
Otsuka Pharma
Zydus Pharma
AstraZeneca
Alembic Pharma
AstraZeneca
InvaGen Pharma
Novartis Pharma
Dr. Reddy's Labs
Allergan
Aurobindo Pharma
Shire Pharma
Lupin
Dexcel Pharma
Sun Pharma
Dexcel Pharma
Dr. Reddy's Labs
Cephalon Inc.
Aurobindo Pharma
Cosmo Techs
Lupin
Pfizer
Dr. Reddy's Labs
Vanda Pharma
Lupin
Forest Labs
InvaGen Pharma
Jazz Pharma
Sun Pharma
Otsuka Pharma
Alkem Labs
Symed Labs
Glenmark Pharma
UCB Inc.
InvaGen Pharma
Unimed Pharma
Dr. Reddy's Labs
Helsinn Healthcare
Dr. Reddy's Labs
Sanofi-Aventis
Glenmark Pharma
Otsuka Pharma
Ajanta Pharma
Merz Pharma
Taro Pharma
Dow Pharma
Taro Pharma
Cubist Pharma
Dr. Reddy's Labs
Bayer Pharma
InvaGen Pharma
Bristol Myers Squibb
Cipla
Janssen Products LP
Lupin
Shire Canada
Lupin
Daiichi Sankyo
Torrent Pharma
Daiichi Sankyo
Alembic Pharma
Daiichi Sankyo
Aurobindo Pharma
Apicore
Aurobindo Pharma
UCB, Inc.
Aurobindo Pharma
Gilead
Aurobindo Pharma
Janssen Biotech
Glenmark Pharma
Sanofi-Aventis
Cadila Healthcare
Sanofi-Aventis
Cadila Healthcare
Roche
Cadila
AstraZeneca AB
Aurobindo
Hyperion Therapeutics
Lupin
Gilead Sciences, Inc.
Aurobindo
Lupin
InvaGen Pharma
Gilead Sciences Inc
Hetero
Shire LLC
Alkem Lab
AbbVie Inc.
Amgen Inc.
Galderma Laboratories, LP
SEEGPharm
Reckitt Benckiser Inc.
Sun Pharma
Takeda Pharma
Dexcel Pharma
Dexcel
Aurobindo
Shionogi Inc
Hi-Tech Pharmacal
Nestle Skin Health
Perrigo Co.
Pfizer
Aurobindo
Arena Pharma
Lupin
Brigham and Women's Hospital InSun Pharma
Brigham and Women's Hospital InStrides Inc.
Brigham and Women's Hospital InCipla
Eli Lilly and Co., ICOS Corp.
Cipla
Brigham and Women's Hospital InAurobindo
Eli Lilly and Co., ICOS Corp.
Alembic Pharma
Brand Name
Beyaz
Moviprep
Prevacid
Xarelto
Gleevec
Abilify
Brilinta
Brilinta
Exelon Patch
Acular LS
Lialda
Omeprazole
Omeprazole
Nuvigili
Uceris
Toviaz
Fanapt
Viibryd
Xyrem
Abilify
Zyvox
Zyrtec-D
Androgel
Aloxi
Multaq
Abilify
Naftin
Onexton
Cubicin
Xarelto
Reyataz
Prezista
Daliresp
Benicar
Benicar
Benicar
LYMPHAZURIN
VIMPAT
EMTRIVA
ZYTIGA
MOZOBIL
MOZOBIL
Aloxi
Nexium 24HR
RAVICTI
Truvada
Antara
Complera
Fosrenol
Humira
Metrogel
Mucinex
Prevacid
Prilosec
Ulesfia
MIRVASO
Toviaz
Belviq
Sensipar
Sensipar
Sensipar
CIALIS
Sensipar
CIALIS
API
Used for
Drospirenone
Birth control
Polyethylene glycol electrolyte soln
Gastro Intestinal
lansoprazole
Stomach ulcers
Rivaroxaban
Blood Thinner
Matinib Mesylate
Anti-cancer
Aripiprazole
Schizophrenia
Ticagrelor
CVS
Ticagrelor
CVS
Rivastigmine
Dementia
Ketorolactromethamine
Ocular Pain
Mesalamine
Ulcerative Colitis
Omeprazole
GI
Omeprazole
GI
Modafinil
CNS
Budesonide
GI
Fesoterodine
Urotherapy
Iloperidone
Schizophrenia
Vilazodone
Anti-depressant
Gamma-hydroxybutyric acid
CNS
Aripiprazole
Schizophrenia
Linezolid
Anti-Infective
Cetirizine
Respiratory
Testosterone
Low Testosterone
Palanosetron
Nausea
Dronedarone
Atrial Fibrillation
Aripiprazole
Schizophrenia
Naftifine Hydrochloride
Fungal Infection
Cindamycin Phosphate and Benzoyl Peroxide Acne
Daptomycin
Antibiotic
Rivaroxaban
Blood Thinner
Atazanavir
HIV
Darunavir
HIV
Roflumilast
Respiratory
Olmesartan
Anti-depressant
Olmesartan
Anti-depressant
Olmesartan
Anti-depressant
isosulfan blue
lymphatic imaging agent
lacosamide
partial-onset seizures
emtricitabine
HIV
abiraterone
Oncology
plerixafor
non-Hodgkin's lymphoma
plerixafor
non-Hodgkin's lymphoma
palonosetron hydrochloride
prevention of acute nausea
esomeprazole magnesium
treatment of acid reflux
Glycerol Phenylbutyrate
urea cycle disorders
emtricitabine / tenofovir disoproxil fumarate HIV
fenofibrate
hypercholesterolemia; dyslipidem
Emtricitabine; Rilpivirine Hydrochloride; TenofoHIV
lanthanum carbonate
end stage renal disease
adalimumab
immunosuppressant
metronidazole
rosacea
guaifenesin / pseudoephedrine hydrochloride bronchial congestion
lansoprazole
stomach ulcers
Omeprazole
Heartburn
benzyl alcohol
anti-parasite
brimonidine
Dermatology
fesoterodine fumarate
overactive bladder
lorcaserin
weight loss
cinacalcet hydrochloride
hyper parathyroidism; hyper calc
tadalafil
erectile dysfunction
tadalafil
erectile dysfunction
Source: Bloomberg, ICICIdirect.com Research
Page 5
Therapy wise performance (| crore)

Therapy
Sep' 16 Sep' 15 YoY (%) Aug' 16 MoM (%)
Anti-Infectives
1558
1460
6.7
1564
-0.4
Cardiac
1127
1007
11.9
1122
0.4
GI
1117
1007
10.9
1136
-1.6
Vitamins
862
764
12.8
852
1.2
Anti Diabetic
810
675
20.0
816
-0.7
Respiratory
779
667
16.8
773
0.9
Pain
711
625
13.7
696
2.1
Neuro
570
509
11.9
553
3.1
Derma
562
508
10.8
555
1.3
Gynaecological
478
439
8.7
475
0.6
Ophthal
167
153
9.5
163
2.9
Vaccines
168
163
2.9
163
2.9
Hormones
169
148
14.2
159
6.4
Anti-Neoplastics
185
127
45.8
149
24.1
Blood Related
108
103
4.8
111
-2.4
Others
140
91
53.3
115
21.6
Urology
106
92
14.6
105
1.2
Anti Malarials
81
79
2.7
78
5.0
Sex Stimulants
50
42
18.1
48
5.2
Stomatologicals
44
38
14.4
43
2.9
Source: AIOCD data base
The Indian pharmaceutical market (IPM) grew 12.6% YoY to | 9792

crore in September. The growth was mainly driven by volumes increase
6.5% followed by new product launches 3.4% and price hikes- 2.7%
The fixed dosage combination (FDCs) related market de-grew 23.5%,
impacting overall growth by ~1%
Drugs under NLEM list declined 1.0% to | 1105 crore while non-NLEM
drugs posted growth of 15.0% to | 8287 crore. Volume growth in NLEM
and non-NLEM was 7.6% and 5.4%, respectively
Among companies under I-direct coverage, Dr Reddys, Unichem,
Lupin, Indoco and Sun registered robust growth of 22.2%, 21.5%,
19.6%, 18.1% and 17.0%, respectively. Ajanta, Alembic, Torrent and
Ipca registered slower than industry growth. Cipla registered muted
growth despite strong growth in domestic respiratory segment
Therapy wise, 10 therapies outpaced IPM growth. Notable among them
with growth rates- anti-diabetic 20.0%, respiratory16.8% and
pain/analgesics 13.7%
In all, 270 new brands were launched in September 2016
On a MAT basis, IPM growth was at 10.9% YoY to | 103820 crore
Domestic companies have grown 13.3% while MNC companies have
grown 10.0% in September 2016
Exhibit 3: Domestic formulations - growth trend
Top brands in Indian pharma market
12.6
10.2
7.0
4.9
7.3
20
15.6
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Feb-16
12.8
Apr-16
Jan-16
10.4
Mar-16
Dec-15
13.3
10
10.4
15
5
0
-5
Indian Pharma Market
Source: AIOCD data base, ICICIdirect.com Research
25
13.8
(%)
10.2 11.2
12.0
Unichem
Torrent
17.0
8.3
9.9
Sun Pharma
Pfizer
Lupin
Novartis
21.5
19.6
18.1
15
10
Ipca Labs
22.2
20
Source: AIOCD data base ; As per AIOCD MAT Sep 2016
Indoco
GSK Pharma
Glenmark
DRL
Cipla
Cadila
Biocon
Exhibit 4: Companies growth in domestic market in September, 2016

Alembic
SubChronic,
20912,
20.1%
Ajanta
Acute,
50238,
48.4%
Nov-15
20
Industry acute to chronic therapy ratio percentage

Chronic,
32670,
31.5%
10.0
25
23.1Oct-15
Sep-15
Sep' 15 Gr. (%)

259.2
22.9
270.3
15.8
244.0
27.4
222.0
35.8
327.4 -10.6
222.8
15.5
202.5
19.6
253.9 -13.2
163.2
28.5
182.6
14.5
(%)
Brand
Company Therapy
Sep' 16
318.5
Spasmo Prox Wockhardt GI
Corex
Pfizer
Respiratory
312.8
Lantus
Sanofi
Anti Diabetic
310.7
Galvus Met Novartis
Anti Diabetic
301.4
Anti-Infectives 292.8
Augmentin GSK
Clavam
Alkem
Anti-Infectives 257.3
Volini
Ranbaxy
Pain
242.1
Becosules Sun Pharma Vitamins
220.3
Voveran
Novartis
Pain
209.8
Pan
Alkem
GI
209.0
IPM grows 12.6% in September
9.3
3.7
2.4
0.4
0
-5
-2.9
Page 6
Therapy wise performance (| crore)
The Indian pharmaceutical market (IPM) grew 12.8% YoY to | 28641

crore in Q2FY17. The growth was mainly driven by volumes increase
6.7% followed by new product launches 3.3% and price hikes- 2.8%
The fixed dosage combination (FDCs) related market de-grew 16.0% to
| 586 crore
Drugs under the NLEM list increased 2.3% to | 3279 crore while nonNLEM drugs posted growth of 14.7% to | 24169 crore. Volume growth
in NLEM was 11.4% while it declined 6.5% in non-NLEM
Among companies under I-direct coverage, Indoco, Unichem, Ipca,
Alembic, Sun, Lupin, Dr Reddys and Glenmark have outperformed IPM
growth
Therapy wise, nine therapies have outpaced IPM growth. Notable
among them with growth rates - anti diabetic 17.8%, respiratory
25.2%, anti-malaria 20.2% and anti-infective 13.6%.
Domestic companies have grown 14.0% while MNCs have grown 8.3%
Exhibit 5: Domestic formulations - quarterly growth trend

19.0
17.0
15.0
13.0
11.0
9.0
7.0
5.0
3.0
1.0
-1.0
-3.0
(%)
Therapy
Q2FY17 Q2FY16 YoY (%) Q1FY17 QoQ (%)
Anti-Infectives
4532
3988
13.6
3510
29.1
Cardiac
3336
3030
10.1
3262
2.3
GI
3384
3048
11.0
3204
5.6
Vitamins
2541
2313
9.8
2395
6.1
Anti Diabetic
2395
2032
17.8
2280
5.0
Respiratory
2238
1788
25.2
1640
36.5
Pain
2058
1822
12.9
1760
17.0
Neuro
1649
1519
8.6
1600
3.1
Derma
1645
1505
9.3
1544
6.5
Gynaecological
1427
1304
9.5
1378
3.6
Ophthal
485
456
6.3
505
-4.1
Vaccines
503
484
3.9
428
17.7
Hormones
476
423
12.7
418
13.9
Anti-Neoplastics
479
418
14.5
399
20.0
Blood Related
326
308
5.8
301
8.4
Others
361
262
38.1
293
23.1
Urology
312
276
13.1
302
3.3
Anti Malarials
219
182
20.2
100 118.7
Sex Stimulants
145
127
14.5
139
4.4
Stomatologicals
129
115
12.1
124
4.3
IPM grows 12.8% in Q2FY17
16.8
13.6
1.5
14.8
3.3
5.2
3.3
8.4
6.6
Q2FY15 Q3FY15
Volumes
2QFY16
Price Increases
2.9
6.4
2.8
3.1
6.7
4.2
Q4FY15 1QFY16
3.3
9.3
5.0
4.6
2.5
12.8
3.0
3.0
4.8
5.1
7.5
11.9
3.3
10.9
4.6
14.7
5.0
1.4
3QFY16 4QFY16
6.7
4.4
-1.0
1QFY17 2QFY17
New Products
[
30.0
20.6
20.0
17.7
16.4
14.8
(%)
15.0
5.0
Cadila
26.4
25.0
10.0
Unichem
Torrent
Sun Pharma
Sanofi
Pfizer
Novartis
Lupin
Ipca
Indoco
Glenmark
GSK Pharma
Dr Reddy's
Cipla
Biocon
Alembic
Ajanta
Exhibit 6: Company wise growth trends in Q2FY17
9.1
7.4
13.7
14.6 14.8
14.5
8.6
5.8
1.7
1.4
8.7
4.1
Page 7
Sun Pharmaceuticals
Acute : Chronic contribution (| cr; MAT Sep16)
150
130
110
90
70
50
Chronic,
4123, 45.5%
Oct-15
SubChronic,
1238, 13.7%
Acute,
3691, 40.8%
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Sun Pharma
Source: NSE, ICICIdirect.com Research
21 to 30
31 to 50
Sep-16
Aug-16
Jul-16
10.2
12.6
17.0
15.6
20.3
11 to 20
3.3
7.6
7.0
9.0
4.9
5.2
4.5
0
Top 10
Jun-16
May-16
Apr-16
20.3
12.8
10.4
7.3
12.3
7%
9%
8.2
13.3
18.1
10
9.9
57%
10.0
9%
10.4
12.5
(%)
15
Mar-16
Feb-16
Jan-16
Dec-15
20
18%
5.2
25
Nov-15
Sep-15
Brands contribution to domestic sales (MAT Sep16)
23.1Oct-15
Exhibit 7: Company growth vis--vis Indian pharma market growth

Sun Pharmaceutical Industries
Others
Exhibit 8: Market share in Indian formulations market
Exhibit 9: Top 10 brands performance
9.6
9.0
Therapy
Volini
Pain
(| crore)
Sep' 16 Sep' 15 Var. (%) Aug' 16 Var. (%)

23.5
18.2
29.1
22.1
6.0
-3.0
Rosuvas
Cardiac
16.5
12.8
28.1
17.0
Istamet
Anti Diabetic
17.4
12.5
39.3
16.6
4.7
7.8
Gemer
Anti Diabetic
17.5
12.6
38.4
17.4
0.3
7.2
Levipil
Neuro
15.3
12.3
24.7
14.3
6.6
6.6
Susten
Gynaecological
12.3
11.7
5.1
12.8
-4.1
Pantocid
Gastro Intestinal
13.1
11.6
13.3
13.5
-2.7
Revital H
Vitamins
15.2
9.4
63.0
14.3
6.3
Pantocid Dsr
Gastro Intestinal
11.4
10.0
14.1
11.1
2.7
Storvas
Cardiac
8.4
9.1
-7.3
8.7
-2.6
8.4
(%)
Brand
8.3 8.3
8.9 8.8 9.0 8.8 8.9 8.8 8.7

8.7 8.6
8.6 8.6
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
6.0
Sun Pharmaceutical Industries
Source: AIOCD data base, ICICIdirect.com Research * Included Ranbaxys sales
Exhibit 10: Contribution of therapies to domestic sales (MAT Sep16)
Exhibit 11: Therapy wise performance
Anti-Infectives
18%
Derma
7%
Gastro
Intestinal
19%
Cardiac
29%
Therapy
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Cardiac
153.6
122.8
25.1
153.6
0.0
Neuro
144.8
121.8
18.9
141.4
2.4
98.1
89.1
10.2
102.2
-4.0
Gastro Intestinal
Neuro
27%
(| crore)
Anti-Infectives
92.7
97.7
-5.1
96.5
-3.9
Derma
42.8
34.9
22.5
76.3
-43.9
Anti Diabetic
77.0
62.6
22.9
59.6
29.3
Vitamins
36.4
28.2
29.3
41.0
-11.2
Pain
63.0
50.6
24.4
35.4
78.2
Respiratory
35.0
25.4
37.4
29.9
16.9
Gynaecological
29.1
29.2
-0.1
33.8
-13.9
Page 8
Cipla
Chronic,
2011,
Acute, 39.9%
2390,
47.5%
Stock Performance
140
120
100
80
60
SubChronic,
634, 12.6%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Cipla
31 to 50
5.4
5.2
5.2
5.1
5.1
5.2
5.1
4.9
4.9
(%)
4.7 4.7
4.6
4.6
4.4
4.5
4.4
4.2
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
4.0
Sep-15
Sep-16
Aug-16
12.6
15.6
Jul-16
10.2
8.6
8.9

Brand
4.9
Cipla
4.8
7.0
8.8
9.0
6.1
Jun-16
May-16
Apr-16
4.9
7.3
Others
0.4
21 to 30
3.5
11 to 20
2.0
Mar-16
Feb-16
12.8
11.5
10.0
10.4
Jan-16
Dec-15
13.3
16.6
10.0
15.9
(%)
8%
4.6
12%
10
10.4
15
12%
21.0
20
44%
Nov-15
Sep-15
25
24%
23.1Oct-15
5.0
Oct-16
Top 10
Aug-16
Cipla
Therapy
(| crore)
Foracort
Respiratory
16.5
15.9
3.8
16.5
-0.3
Budecort
Respiratory
12.6
13.4
-5.3
12.0
5.4
Asthalin
Respiratory
12.1
10.9
11.0
11.4
6.6
Duolin
Respiratory
13.1
10.2
28.8
12.4
6.1
Seroflo
Respiratory
11.6
11.2
3.1
11.4
1.3
Aerocort
Respiratory
7.9
8.2
-3.9
8.0
-1.7
Azee
Anti-Infectives
7.7
9.4
-18.4
7.6
0.8
Montair Lc
Respiratory
8.1
6.7
20.0
8.0
0.3
Novamox
Anti-Infectives
6.3
7.1
-11.6
5.6
12.3
Advent
Anti-Infectives
7.5
6.6
12.8
7.3
2.4
Other
18%
Respiratory
30%
Urology
5%
Gastro
Intestinal
8%
Cardiac
12%
Anti-Infectives
27%
Therapy
Respiratory
Anti-Infectives
(| crore)
Sep' 16
135.1
Sep' 15
124.3
YoY (%)
8.7
Aug' 16
132.3
MoM (% )
2.2
110.7
121.6
- 8.9
113.4
- 2.4
Cardiac
50.1
48.0
4.6
51.1
- 1.9
Gastro Intestinal
34.0
33.2
2.5
37.5
- 9.2
Urology
Neuro
20.9
13.4
20.2
15.3
3.5
-1 2.2
20.1
13.6
4.0
- 1.1
Ophthal
13.6
14.4
- 5.6
13.4
1.3
Pain
15.5
15.4
0.8
15.8
- 2.0
Derma
V itamins
12.3
7.5
11.5
7.6
6.8
- 1.4
12.0
7.9
2.6
- 5.5
Page 9
Dr. Reddys Labs
Stock Performance) Stock Performance

Chronic,
727, 29.3%
140
120
100
80
60
SubChronic,
520, 21.0%
Acute,
1235,
49.8%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Dr. Reddys
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Sep-15
Oct-15
Top 10
11 to 20
21 to 30
31 to 50
Others
2.8
2.7
2.7
2.6
2.4
2.4
2.6
2.3
2.3
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
2.2
2.3
2.2
2.2
2.1
Sep-15
2.3
Sep-16
2.5
2.5
Aug-16
2.6
(%)
12.6
22.2
17.3
10.2
4.8
7.0
1.5

Brand
2.2
Dr. Reddys Laboratories
2.2
9.0
4.1
4.9
7.3
-10
2.3
15.6
31.7
12.8
26.5
-1.4
6.7
10%
10.0
23.6
10
16%
7.5
12%
10.4
(%)
20
10.4
30
29%
23.1
30.7
33%
13.3
27.4
40
Dr. Reddys Laboratories
Gastro
Intestinal
21%
Cardiac
14%
Anti-Infectives
8%
Respiratory
9%
(| crore)
Omez
Gastro Intestinal
9.4
10.8
-12.6
8.9
6.2
Omez D
Gastro Intestinal
10.2
8.4
21.1
9.1
11.9
Econorm
Gastro Intestinal
4.6
5.7
-20.1
5.5
-16.1
Grafeel
Anti-Neoplastics
5.0
5.7
-12.4
6.3
-21.6
Stamlo
Cardiac
4.9
5.6
-12.4
4.7
4.7
Nise
Pain
6.1
5.9
3.2
5.8
5.3
Razo D
Gastro Intestinal
5.4
4.6
17.0
5.2
3.5
Atarax
Respiratory
6.3
4.0
56.6
5.6
12.9
Mintop
Derma
2.8
3.8
-24.6
2.9
-2.4
Razo
Gastro Intestinal
5.2
4.0
29.8
5.1
2.6

Other
36%
Therapy
AntiNeoplastics
12%

Therapy
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
Gastro Intestinal
45.4
43.5
4.3
44.5
MoM (%)
2.0
Cardiac
29.5
30.0
-1.7
27.7
6.5
Anti-Neoplastics
42.4
17.1
148.4
35.6
19.2
Respiratory
22.1
17.2
28.2
21.5
3.0
Anti-Infectives
22.9
16.9
35.5
21.1
8.2
Pain
14.9
14.0
6.3
14.5
2.8
Derma
11.7
11.7
0.0
11.4
2.6
Anti Diabetic
13.9
13.2
5.8
13.5
3.4
Urology
8.9
7.7
16.1
8.7
3.1
Neuro
7.6
7.0
8.2
7.3
4.3
Page 10
Lupin
Stock Performance
Chronic,
1706,
49.1%
140
120
100
80
60
SubChronic,
658, 18.9%
Acute,
1113,
32.0%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Lupin
Aug-16
13.5
11.1
4.7
6.7
7.0
15.8
14.9
Jul-16
May-16
8.8
11.7
Jun-16
Apr-16
Mar-16
20.5
Feb-16
12.6
18.4
10.1
12.9
14.5
13.1
Jan-16
Dec-15
Nov-15
9.8
4.7
9.9
9%
12
7.2
13%
(%)
11%
21.8
20
10.6
20%
12.1
47%
13.7
20.9
28
23.0 Oct-15
Aug-15
Sep-15
-4
Top 10
11 to 20
21 to 30
31 to 50
Others

3.5
3.4 3.4
3.4 3.4 3.3 3.3
Brand
Therapy
(| crore)
Aug' 16 Aug' 15 Var. (%) July' 16 Var. (%)
Gluconorm-G
Anti Diabetic
15.0
11.4
30.8
14.6
2.2
Budamate
Respiratory
8.4
6.1
39.0
7.6
11.4
Tonact
Cardiac
7.7
8.4
-8.1
7.5
3.6
Rablet-D
Gastro Intestinal
5.2
4.7
12.1
5.4
-3.5
2.7
Rablet
Gastro Intestinal
4.5
4.5
1.1
4.5
1.4
2.5
Tazar
Anti-Infectives
4.2
3.5
20.2
3.8
10.0
2.3
Esiflo
Respiratory
4.0
4.4
-7.5
3.6
11.4
3.3 3.3 3.3 3.3
3.3
3.1
3.2 3.2 3.2
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
2.9
Aug-15
(%)
Lupin
Lupin
Telekast-L
Respiratory
4.0
3.4
18.9
4.2
-4.4
Cetil
Anti-Infectives
3.9
3.4
14.2
4.2
-6.4
Ramistar
Cardiac
3.7
4.3
-15.2
3.5
3.7
Cardiac
24%
Other
22%
Gastro
Intestinal
8%
Anti Diabetic
12%
Anti-Infectives
21%
Respiratory
13%
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
Cardiac
71.9
70.0
2.8
68.5
5.0
Anti-Infectives
63.9
62.1
2.9
60.8
5.0
Respiratory
38.0
30.8
23.4
34.4
10.6
Anti Diabetic
38.2
29.5
29.4
36.9
3.5
Gastro Intestinal
25.4
23.0
10.2
25.1
1.3
Vitamins
15.8
16.8
-5.9
15.6
1.3
Neuro
14.4
14.0
2.9
13.8
4.4
Pain
13.2
12.8
3.3
12.7
3.4
Gynaecological
11.4
9.8
16.7
10.7
6.8
2.0
1.8
12.6
2.0
0.9
Ophthal
(| crore)
Therapy
Page 11
Cadila Healthcare
Stock Performance
Chronic,
1706,
49.1%
140
120
100
80
60
SubChronic,
658, 18.9%
Acute,
1113,
32.0%
Oct-15
Dec-15
Feb-16
Apr-16
CNX Pharma
Jun-16
Aug-16
Oct-16
Cadila Healthcare
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Sep-15
Oct-15
12.6
15.6
13.8
7.0
9.0
5.0
7.4
7.7
4.9
10.2
12.8
10.4
13.4
7.3
8.9
Others
8.3
(%)
31 to 50
2.9
21 to 30
5.0
11 to 20
10
6.1
Top 10
15
10.4
12.4
13%
9%
13.3
20
11%
12.5
25
20%
10.0
47%
23.1
24.6
30
Cadila Healthcare
4.1
3.8
3.9 3.9 3.9
4.0
3.9
3.8
3.8
Aug-16
Jul-16
Jun-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
3.7
3.7
Sep-16
3.9
4.0
May-16
4.2
4.1
4.0
3.9
3.8
3.7
3.6
3.5
3.4
Sep-15
(%)
Cadila Healthcare
Therapy
Skinlite
Derma
14.7
14.0
5.2
13.9
5.9
Atorva
Cardiac
9.1
10.4
-12.3
9.0
0.8
Mifegest Kit
Gynaecological
5.2
8.8
-40.9
9.4
-44.4
Deriphyllin
Respiratory
9.8
8.5
15.0
9.2
6.6
Pantodac
Gastro Intestinal
9.2
8.0
15.1
9.1
0.7
Zyrop
Blood Related
7.0
4.8
45.3
6.5
8.1
Aten
Cardiac
5.4
5.4
-0.3
5.1
5.7
Falcigo
Anti Malarials
8.9
8.3
7.4
6.5
37.1
Amlodac
Cardiac
5.2
6.1
-15.2
4.8
6.7
Formonide
Respiratory
5.2
5.1
1.7
5.2
1.2

Cardiac
16%
Other
39%
Gastro
Intestinal
13%
Pain
10%
(| crore)
Brand
Gynaecological
11%
Respiratory
11%
(| crore)
Therapy
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Cardiac
55.2
53.1
4.0
54.6
1.1
Gastro Intestinal
47.9
44.4
7.8
47.7
0.4
Respiratory
39.8
35.8
10.9
38.5
3.3
Gynaecological
31.2
33.2
-6.2
33.8
-7.7
Pain
37.2
32.2
15.2
36.1
2.9
Derma
28.0
25.3
10.6
26.9
3.9
Anti-Infectives
33.5
26.5
26.5
30.9
8.3
38.1
Anti-Neoplastics
31.7
18.3
73.2
23.0
Vitamins
17.8
13.8
28.4
17.5
1.7
Hormones
8.2
7.9
4.2
7.2
13.4
Page 12
GlaxoSmithKline
Stock Performance
Chronic,
417, 12.8%
Acute,
2130,
65.6%
140
120
100
80
60
SubChronic,
701, 21.6%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Oct-16
GSK Pharma
21 to 30
31 to 50
Sep-16
Aug-16
12.6
15.6
Jul-16
Jun-16
4.0
7.0
10.2
-2.9
4.5
0.3
-9.5
-7.2
-6.7
4.9
7.3
9.0
12.8
-5
-10
11 to 20
May-16
Apr-16
Mar-16
Feb-16
Jan-16
2.2
13.3
Dec-15
Nov-15
10.0
10.4
4.7
16%
6.9
(%)
4.5
10
52%
9%
1.1
15
10%
10.4
20
21.2
Sep-15
25
13%
23.1
Oct-15
Top 10
Aug-16
-15
Others
Glaxosmithkline Pharmaceuticals


3.6
3.5
3.4
3.4 3.4
3.4
3.3
3.1 3.1
3.0
3.0 3.0
3.0
2.9
2.8
3.0 2.9
Brand
Therapy
Augmentin
Anti-Infectives
(| crore)

25.2
27.9
-9.6
25.7
-2.0
-8.4
Synflorix
Vaccines
16.8
16.3
2.8
18.3
Calpol
Pain
23.7
19.6
21.2
23.5
0.8
Zinetac
Gastro Intestinal
13.5
12.1
11.9
13.1
3.4
10.7
14.9
11.6
5.7
Ceftum
Anti-Infectives
12.8
11.7
10.1
12.2
5.3
Rotarix
Vaccines
7.5
16.5
-54.5
8.0
-6.1
Betnesol
Hormones
9.7
10.6
-8.7
8.6
12.2
Sep-16
12.2
Aug-16
Hormones
Jun-16
12.7
Eltroxin
May-16
2.4
Apr-16
14.0
8.6
Mar-16
10.1
-16.0
Feb-16
-9.9
11.6
Jan-16
12.8
9.7
Dec-15
11.5
Derma
Nov-15
Derma
Betnovate N
Oct-15
Betnovate C
Sep-15
2.6
Jul-16
(%)
3.2
Glaxosmithkline Pharmaceuticals

Other
26%
Anti-Infectives
23%
Respiratory
8%
Derma
18%
Pain
10%
Vaccines
15%

Therapy
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Anti-Infectives
65.9
68.7
-4.1
66.7
-1.2
Derma
43.7
54.0
-19.2
45.4
-3.8
Vaccines
40.1
43.1
-7.0
43.2
-7.1
Pain
35.5
30.6
16.0
34.5
2.8
Respiratory
24.0
24.0
0.0
23.0
4.3
Hormones
22.7
22.3
1.4
20.9
8.2
Vitamins
24.7
22.5
9.6
23.4
5.5
Gastro Intestinal
15.4
14.4
7.2
14.9
3.7
Cardiac
4.7
6.2
-23.6
4.5
5.6
Gynaecological
2.1
3.1
-31.7
2.2
-5.0
Page 13
Wockhardt
Stock Performance
400
350
300
250
200
150
100
50
0
Chronic,
279,
20.5%
Acute,
931,
68.4%
SubChronic
151,
11.1%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Wockhardt
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Sep-15
Oct-15
60
14%
11 to 20
21 to 30
31 to 50
3.9
12.6
15.6
10.2
10.2
1.8
7.0
9.0
9.0
1.3
2.4
5.4
Others
4.9
4.5
7.3
12.8
38.2
13.3
29.6
10.4
9.8
10
10.4
(%)
20
15%
Top 10
23.1
30
10.0
55%
50.3
40
8%
42.5
50
8%
Wockhardt

Brand
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
Therapy
31.1
31.9
-2.4
27.5
13.1
Vitamins
7.4
5.6
31.9
7.6
-2.5
Tryptomer
Neuro
5.6
5.2
7.7
5.7
-3.0
Bro Zedex
Respiratory
4.4
4.4
0.5
4.8
-7.6
Methycobal
Vitamins
4.2
3.9
9.1
4.5
-5.4
Biovac V
Vaccines
2.6
5.3
-51.4
3.4
-24.9
Zedex
Respiratory
3.3
3.0
12.2
3.4
-2.2
Biovac A
Vaccines
3.9
5.1
-23.4
4.1
-6.7
Ace Proxyvon
Pain
2.2
3.1
-29.8
2.0
7.1
Wosulin
Anti Diabetic
2.5
2.1
18.9
2.7
-7.9
Practin
1.28
1.28
Sep-16
Aug-16
Jul-16
Jun-16
May-16
1.27 1.25
1.27
1.21
Apr-16
Mar-16
Feb-16
1.36 1.37 1.33

1.33
Jan-16
Dec-15
Nov-15
Oct-15
1.39 1.41 1.38
Wockhardt
(| crore)
Spasmo Proxyvon PluGastro Intestinal
Sep-15
(%)
Gastro
Intestinal
25%
Other
32%
Vitamins
15%
Anti Diabetic
7%
Neuro
8%
Respiratory
13%
Therapy
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Gastro Intestinal
33.0
33.1
-0.3
29.4
12.3
Vitamins
18.1
16.0
13.2
18.9
-4.2
Respiratory
0.7
15.9
13.4
18.4
15.7
Neuro
9.8
8.6
14.4
9.7
1.3
Anti Diabetic
7.7
6.5
17.9
8.0
-4.0
Anti-Infectives
9.5
10.0
-5.5
8.6
9.9
Derma
8.7
8.0
7.9
8.3
5.0
Pain
6.1
7.8
-21.0
6.3
-1.8
Vaccines
6.9
10.4
-33.4
7.7
-10.1
Hormones
2.9
2.5
13.7
2.5
12.7
Page 14
Glenmark Pharmaceuticals
Stock Performance
Chronic,
904, 36.2%
200
180
160
140
120
100
80
60
SubChronic,
580, 23.2%
Acute,
1014,
40.6%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Oct-16
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
43.5
12.6
12.0
15.6
20.9
10.2
8.5
7.0
9.0
7.3
14.7
12.8
19.5
10.4
16.2
13.3
18.5
23.1
7.1
Others
8.8
31 to 50
4.9
8.6
21 to 30
10.0
12%
10%
11.4
14%
11 to 20
Sep-15
(%)
34%
10.4
13.0
30%
50
45
40
35
30
25
20
15
10
5
0
Oct-15
Top 10
Aug-16
Glenmark

Therapy
Telma
Cardiac
12.7
14.5
Telma H
Cardiac
12.5
Ascoril Plus
Respiratory
11.6
Candid
Derma
2.1
Candid-B
1.9
2.7
2.5
2.4
2.5 2.4
2.6
2.5
2.4 2.4
2.3
2.4
2.4
2.3 2.3
2.4
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
2.2
Sep-15
(%)
(| crore)
Brand

Other
12%
Derma
29%
Anti-Infectives
13%
Respiratory
16%
-12.7
13.6
-6.9
11.6
7.6
12.9
-3.4
9.0
28.4
11.4
2.0
8.8
7.7
14.0
9.1
-3.1
Derma
9.3
8.1
15.0
8.6
8.4
Telma Am
Cardiac
6.6
6.3
4.1
6.9
-4.5
Ascoril Ls
Respiratory
6.0
4.1
45.1
5.5
8.1
Onabet
Derma
4.8
3.4
39.8
4.9
-2.0
Ascoril D
Respiratory
3.2
3.0
6.9
3.5
-8.8
Zita Plus
Anti Diabetic
2.7
2.4
9.5
3.0
-9.6
Anti Diabetic
8%
Cardiac
22%

Therapy
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
Derma
64.1
58.4
9.8
63.6
MoM (%)
0.8
Cardiac
45.0
44.5
1.1
47.4
-5.1
Respiratory
40.4
31.2
29.5
40.4
0.0
Anti-Infectives
36.0
30.7
17.1
36.9
-2.5
Anti Diabetic
-8.5
13.4
20.6
-34.9
14.7
Gastro Intestinal
8.9
5.1
74.3
8.2
8.6
Vitamins
5.1
5.7
-10.8
5.2
-3.2
Gynaecological
5.8
4.5
27.6
5.9
-1.8
Pain
4.2
4.3
-2.8
4.2
-0.9
Ophthal
4.6
3.6
27.7
4.4
3.8
Page 15
Torrent Pharmaceuticals
Stock Performance
Chronic,
1182,
51.0%
200
160
120
80
40
SubChronic,
583, 25.1%
Oct-15
Acute, 553,
23.8%
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Oct-16
Torrent Pharma
Others
Sep-16
Aug-16
9.3
12.7
12.6
15.6
Jul-16
10.2
4.1
7.0
9.0
1.4
4.9
7.3
2.4
Jun-16
May-16
Apr-16
Mar-16
Feb-16
12.8
10.2
10.4
-5
-2.4
31 to 50
-3.0
21 to 30
Jan-16
Dec-15
13.3
0
11 to 20
7.4
9%
5.4
12%
10.4
16.0
10
14%
10.0
(%)
15
3.8
20
33%
19.9
32%
Nov-15
Sep-15
25
23.1Oct-15
Top 10
Aug-16

2.4
2.33
2.3
2.3
(%)
2.32
2.28
2.22
2.2
2.19
2.29
2.25
2.22
2.23
2.21
2.18
2.16
2.2
2.16
2.1
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
2.1
Cardiac
29%
Pain
8%
Gastro
Intestinal
15%
Vitamins
16%
Therapy
Shelcal
Vitamins
17.9
16.6
7.9
17.5
2.3
Chymoral Forte
Pain
10.8
8.8
23.7
11.2
-3.6
Nikoran
Cardiac
8.1
7.3
10.2
7.6
5.8
Dilzem
Cardiac
5.7
5.3
7.6
5.4
4.5
Nebicard
Cardiac
5.8
4.9
17.4
5.7
1.6
Azulix-Mf
Anti Diabetic
5.9
4.7
25.4
6.1
-4.2
Nexpro Rd
Gastro Intestinal
5.9
4.4
36.1
5.3
11.6
Nexpro
Gastro Intestinal
5.0
4.2
18.8
4.7
6.9
Shelcal Ct
Vitamins
4.7
3.4
36.9
4.5
5.1
Alprax
Neuro
3.5
3.3
6.4
3.4
1.4

Other
16%
(| crore)
Brand
Neuro
16%

Therapy
Sep' 16
(| crore)
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Cardiac
59.3
55.6
6.7
58.6
1.2
Neuro
33.3
30.8
8.1
33.9
-1.7
Vitamins
34.9
30.4
14.7
33.8
3.1
Gastro Intestinal
31.8
29.0
9.6
31.9
-0.2
Pain
17.5
14.5
20.7
17.8
-1.4
Anti Diabetic
13.5
11.5
16.7
13.8
-2.3
Anti-Infectives
8.3
9.4
-12.3
8.7
-4.6
Derma
6.0
5.0
20.4
5.9
2.3
Gynaecological
3.0
3.5
-13.0
3.0
-0.2
Urology
1.1
0.8
31.0
1.0
7.0
Page 16
Ipca Laboratories
Stock Performance
Acute, 890,
66.7%
150
125
100
75
50
Chronic,
359, 26.9%
SubChronic, 84,
6.3%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Ipca
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Sep-15
Oct-15
21 to 30
31 to 50
1.5
1.4
Sep-16
1.4
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
1.3 1.2 1.2 1.2

1.2 1.2 1.2 1.2
Oct-15
28.0
8.3
12.6
15.6
1.5 1.4
Sep-15
(%)
10.2
18.1
4.1

2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
Ipca Laboratories
3.3
7.0
4.9
7.3
9.0
12.8
11.5
9.1
10.4
13.3
1.5
3.7
Others
3.7
11 to 20
11.8
10
16%
10.0
(%)
11%
15
10.4
20
12%
6.4
25
38%
Top 10
23.1
25.9
30
23%
Ipca Laboratories
Pain
25%
Anti-Infectives
6%
Gastro
Intestinal
8%
Cardiac
17%
Brand
Therapy
Zerodol Sp
Pain

8.2
7.9
4.1
8.5
-4.0
Zerodol P
Pain
7.4
8.8
-15.0
9.6
-22.2
Hcqs
Anti Malarials
5.4
5.3
0.6
5.1
5.7
Larinate
Anti Malarials
8.9
7.8
14.5
8.2
9.0
Rapither-Ab
Anti Malarials
7.3
5.0
45.5
9.2
-20.2
Lariago
Anti Malarials
6.1
5.6
8.7
7.5
-18.1
Glycinorm M
Anti Diabetic
3.4
3.1
9.4
3.3
0.2
Folitrax
Anti-Neoplastics
2.7
2.7
1.8
3.1
-10.7
Lumerax
Anti Malarials
4.9
4.4
10.7
4.6
6.5
Zerodol
Pain
2.2
2.6
-15.0
2.3
-2.1

Other
24%
(| crore)
Anti Malarials
20%

Therapy
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
Pain
31.9
31.8
0.3
34.7
MoM (%)
-7.9
Anti Malarials
36.9
33.4
10.4
39.4
-6.4
Cardiac
18.2
18.0
1.0
19.2
-5.2
-1.3
Gastro Intestinal
9.3
9.5
-2.1
9.4
Anti-Infectives
8.4
7.4
13.5
8.6
-1.6
Anti Diabetic
6.0
5.6
6.7
6.1
-2.3
Respiratory
5.4
4.8
11.6
5.7
-5.4
Anti-Neoplastics
5.4
4.3
24.7
5.0
8.4
Neuro
5.3
3.5
52.3
5.0
6.0
Derma
4.2
3.3
27.0
4.1
2.9
Page 17
Biocon
Stock Performance
Chronic,
245, 70.5%
140
120
100
80
SubChronic, 30,
8.6%
Acute, 73,
20.9%
60
Oct-15
Dec-15
Feb-16
Jun-16
Aug-16
Oct-16
Biocon
31 to 50
-11.2
2%
21 to 30
-10
Others
Sep-16
Aug-16
9.9
11.4
10.2
7.0
3.5
9.0
9.4
4.9
7.7
12.6
15.6
Jul-16
Jun-16
May-16
Apr-16
Mar-16
7.3
12.8
11.3
Feb-16
Jan-16
10.4
5.3
5.2
10.0
14.5
1.2
0
-5
-0.8
(%)
5%
10.0
10
5%
11 to 20
10.4
15
10%
13.3
20
78%
Dec-15
Nov-15
Sep-15
25
23.1
Oct-15
Top 10
Apr-16
CNX Pharma
-15
Biocon

0.39
Brand
0.38
0.37
0.36
0.35
0.33
0.33
0.34 0.34 0.35
0.34
0.34
Therapy
(| crore)
Insugen
Anti Diabetic
6.9
7.3
-6.0
7.7
-10.3
Basalog
Anti Diabetic
5.0
4.6
8.3
5.6
-10.8
Erypro
Blood Related
4.0
1.4
188.8
2.4
68.3
Canmab
Anti-Neoplastics
2.2
1.0
113.8
1.8
19.0
0.29
Abraxane
Anti-Neoplastics
0.6
1.4
-57.6
1.7
-64.8
0.27
Insugen R
Anti Diabetic
1.5
1.4
2.6
1.5
-4.4
Blisto Mf
Anti Diabetic
1.3
1.5
-13.4
1.3
-1.7
Biomab Egfr
Anti-Neoplastics
0.3
0.8
-64.6
1.9
-84.9
Psorid
Anti-Neoplastics
0.8
0.6
35.7
0.6
24.8
Insugen N
Anti Diabetic
0.6
0.7
-24.5
0.6
-12.8
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
0.31
0.32
0.30
Sep-16
0.32
Dec-15
Oct-15
Nov-15
0.31
0.31
Sep-15
(%)
Biocon

Cardiac
5%
Blood Related
7%
Derma
3%
AntiNeoplastics
23%
Other
4%

Therapy
Anti Diabetic
Anti-Neoplastics
Anti Diabetic
58%
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
16.3
16.8
-2.7
17.9
-9.0
5.8
5.4
7.7
7.4
-21.8
Blood Related
4.1
1.4
193.8
2.4
68.7
Cardiac
1.4
1.5
-6.7
1.3
10.0
Derma
0.8
0.7
18.0
0.7
12.7
Anti-Infectives
0.7
0.6
20.9
0.5
32.7
Others
0.2
0.2
30.4
0.2
5.6
Gastro Intestinal
0.3
0.4
-23.7
0.1
223.4
Vitamins
0.1
0.2
-49.0
0.1
-11.2
Pain
0.1
0.0
189.6
0.0
197.7
Page 18
Pfizer
Stock Performance
Chronic,
461, 15.7%
Acute,
1908,
65.0%
200
160
120
80
40
SubChronic,
566, 19.3%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Pfizer
21 to 30
31 to 50
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
12.6
15.6
3.0
6.8
2.4
10.2
7.0
7.2
4.9
2.7
7.3
3.4
9.0
12.8
5.1
-1.0
-5
11 to 20
Feb-16
Jan-16
Dec-15
10.4
10.0
-3.5
1.6
19%
3.3
(%)
10
8.9
15
50%
10%
10.4
20
13.3
23.1
25.0
25
10%
Nov-15
Sep-15
30
11%
Oct-15
-10
Others
Pfizer

3.0
2.93
2.90
2.93
2.8
2.95
2.90 2.91 2.92

2.83
2.88
2.84
(%)
2.73
2.79
2.72
2.6
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
2.4
Aug-15
Oct-16
Top 10
Aug-16
Pfizer
Therapy
Corex
Respiratory
24.9
27.7
-10.1
24.4
2.1
Becosules
Vitamins
21.3
20.5
4.0
20.8
2.7
Dolonex
Pain
12.7
11.0
15.3
12.1
5.1
Gelusil Mps
Gastro Intestinal
11.5
11.7
-1.5
12.3
-6.3
Magnex
Anti-Infectives
10.8
12.9
-16.6
12.7
-15.2
Minipress Xl
Cardiac
9.9
11.3
-12.5
13.1
-24.4
Mucaine
Gastro Intestinal
10.3
8.8
17.9
10.5
-1.2
Wysolone
Hormones
11.0
10.7
3.0
10.4
6.2
Folvite
Blood Related
6.3
7.1
-11.8
6.0
5.1
Dalacin C
Anti-Infectives
6.8
6.5
5.2
6.6
2.6

Anti-Infectives
15%
Other
41%
Respiratory
14%
Gastro
Intestinal
11%
Hormones
9%
(| crore)
Brand
Vitamins
10%

Therapy
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Anti-Infectives
35.9
42.7
-15.9
37.7
-4.9
Respiratory
34.3
33.6
2.3
33.5
2.6
Gastro Intestinal
26.5
25.2
5.2
27.6
-3.8
Vitamins
27.2
26.5
2.8
27.3
-0.2
Hormones
25.7
24.5
4.9
23.7
8.6
Gynaecological
21.6
19.5
11.0
21.1
2.2
Neuro
15.7
17.5
-10.1
16.4
-3.9
Cardiac
15.9
16.6
-4.6
19.1
-16.9
Pain
17.4
15.6
11.4
17.3
0.6
Vaccines
13.9
6.6
110.9
12.3
13.1
Page 19
Novartis
Stock Performance
Chronic,
505, 43.4%
190
140
90
SubChronic,
160, 13.7%
Acute, 501,
43.0%
40
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Novartis India
-5
11 to 20
21 to 30
31 to 50
Sep-16
Novartis India
1.3
1.21
1.2
1.16 1.17 1.16 1.15
1.15 1.16
1.19 1.19
1.1
1.10 1.10
1.06
1.02
1.1
Brand
Therapy
Galvus Met
Anti Diabetic
(| crore)

28.8
22.5
28.1
27.0
6.9
Voveran
Pain
21.2
15.9
33.0
19.7
7.7
Galvus
Anti Diabetic
10.0
10.1
-0.2
10.1
-0.5
Rabipur (Novartis)
Vaccines
5.4
6.6
-18.5
8.2
-34.3
2.8
Tegrital
Neuro
4.5
4.1
10.4
4.4
1.0
Voveran
Pain
3.6
3.2
12.7
3.5
1.1
0.9
Regestrone
Gynaecological
3.1
3.6
-14.8
2.5
22.7
Methergin
Gynaecological
2.5
2.8
-10.5
2.4
6.1
Syntocinon
Gynaecological
2.7
2.3
17.7
2.4
13.5
Macalvit
Vitamins
1.8
1.9
-1.1
1.7
11.9
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
1.0
Aug-16
(%)
12.6
-10
Others
1.2
3.7
6.0
-5.2
80%
Aug-16
10.2
7.0
10.2
3.9
9.0
18.7
15.6
Jul-16
Jun-16
May-16
Apr-16
Mar-16
7.3
21.6
12.8
25.1
Feb-16
Jan-16
Dec-15
10.4
14.9
4.9
13.3
17.3
10
11.9
(%)
15
10.4
20
Nov-15
25
10.0
20.4
Sep-15
30
2%
11% 3%4%
23.1 Oct-15
27.4
Top 10
Oct-16
Novartis India

Therapy
Other
14%
Gynaecological
8%
Anti Diabetic
36%
Vaccines
9%
Vitamins
10%
Pain
23%
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Anti Diabetic
39.5
33.3
18.6
37.6
4.9
Pain
26.2
20.8
26.0
24.6
6.5
Vitamins
8.8
9.7
-10.0
8.8
-0.5
Vaccines
5.5
6.7
-18.6
8.3
-34.1
13.6
Gynaecological
8.4
9.0
-7.1
7.4
Neuro
4.5
5.0
-9.1
4.4
2.8
Anti-Infectives
2.9
4.7
-38.4
5.4
-46.7
10.3
Respiratory
2.1
2.5
-12.6
1.9
Cardiac
0.7
1.2
-43.5
0.7
-6.0
Anti-Neoplastics
0.8
3.4
-78.1
0.5
40.0
Page 20
Unichem Laboratories
Stock Performance
Chronic,
544,
58.2%
160
130
100
70
Oct-15
Acute,
335,
35.8%
SubChronic,
57, 6.1%
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Unichem Labs
21 to 30
31 to 50
Others

1.10
1.00
0.94
0.90
0.89
0.94
0.89 0.90 0.90
0.95
0.92
0.92
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
0.84 0.85
Nov-15
Oct-15
Sep-15
0.84 0.82
Aug-15
12.6
15.6
10.2
14.1
7.0
4.0
2.3
0.6
4.9
7.3
9.0
12.8

Brand
(%)
10.0
10.4
9.9
0.80
3.1
0
2.7
11 to 20
3.8
9%
Top 10
13.3
14%
12%
11.3
10
10.0
(%)
15
10.4
20
33%
21.5
26.4
23.1
28.3
30
25
32%
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Sep-15
Oct-15

Other
12%
Cardiac
41%
Gastro
Intestinal
12%
Neuro
14%
(| crore)
Losar H
Cardiac
8.7
6.2
39.7
8.4
3.2
Ampoxin
Anti-Infectives
6.6
7.2
-8.5
7.4
-11.3
Losar
Cardiac
6.0
5.2
17.0
5.9
2.5
Unienzyme
Gastro Intestinal
4.9
4.6
7.4
5.5
-9.4
Vizylac
Gastro Intestinal
3.8
2.7
38.8
3.5
7.5
Trika
Neuro
2.2
2.1
6.0
1.9
16.3
Serta
Neuro
1.9
1.6
13.8
2.0
-7.6
Unistar (Unichem)
Cardiac
1.7
1.4
23.3
1.7
-0.1
Arkamin
Cardiac
1.6
1.1
51.7
2.1
-23.7
Telsar
Cardiac
1.4
1.3
5.7
1.3
5.6
Pain
4%
Therapy
Anti-Infectives
17%
(| crore)
Therapy
Sep' 16
Sep' 15
YoY (%)
Aug' 16
Cardiac
34.9
28.4
22.7
34.8
MoM (%)
0.4
Anti-Infectives
15.4
14.7
4.7
16.3
-5.6
Neuro
11.7
9.1
29.3
11.9
-1.6
Gastro Intestinal
10.3
8.7
18.9
10.7
-4.1
Pain
4.1
2.9
42.6
4.0
3.5
Anti Diabetic
3.9
2.2
79.1
3.8
3.1
Respiratory
2.2
1.9
15.7
2.2
0.3
Vitamins
2.1
1.7
23.0
2.1
1.2
Derma
2.1
1.6
32.1
2.0
0.9
Gynaecological
0.3
0.4
-18.7
0.4
-10.3
Page 21
Indoco Remedies
Stock Performance
140
120
100
80
60
Chronic,
41, 5.5%
Acute,
619,
83.0%
Oct-15
SubChronic
85, 11.4
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Aug-16
Oct-16
Indoco
Top 10
11 to 20
21 to 30
31 to 50
Others
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
33.7
0.8 0.8
0.8
0.8
0.7 0.7
0.7 0.7
0.7 0.7 0.7
0.7
0.7
0.7
0.6
0.7
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
0.6
Sep-15
12.6
18.1
15.6
10.2
27.8
7.0
11.5
9.0
-0.9
0.7
5.2
4.9
7.3
12.8
5.4
10.4
13.3
11.0
0.9
Aug-15
Indoco Remedies
(%)
10.0
23.1
0.7
5.6
15%
10.3
9%
Nov-15
Sep-15
(%)
49%
16.2
10%
10.4
17%
40
35
30
25
20
15
10
5
0
-5
-10
-6.4
Oct-15
Indoco Remedies
Brand
Therapy
Febrex Plus
Respiratory
(| crore)

9.1
6.2
46.3
10.8
-15.6
Oxipod
Anti-Infectives
5.5
3.9
40.7
6.3
-13.4
Cyclopam
Gastro Intestinal
3.7
3.6
2.7
4.6
-20.0
Sensodent-K
Stomatologicals
3.4
2.6
29.7
3.2
6.4
Cital
Urology
3.0
2.7
11.8
2.9
5.7
Atm
Anti-Infectives
3.5
2.8
24.3
3.7
-3.9
Karvol Plus
Respiratory
2.4
1.8
33.9
2.2
11.6
Cloben G
Derma
2.1
1.9
11.5
2.3
-7.8
Sensodent-Kf
Stomatologicals
1.6
1.7
-1.3
1.8
-11.0
Cyclopam
Gastro Intestinal
1.7
1.5
14.6
2.5
-30.8

Other
25%
Vitamins
7%
Respiratory
19%
Therapy
Stomatological
s
16%
(| crore)
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
15.3
11.7
30.8
17.4
-11.8
Anti-Infectives
15.2
12.6
20.5
16.7
-8.8
Stomatologicals
10.6
8.9
19.0
10.5
0.5
Gastro Intestinal
8.2
7.9
4.4
10.5
-21.9
Vitamins
5.5
4.3
27.2
5.5
-0.2
Urology
3.5
3.1
12.2
3.3
3.2
Ophthal
3.5
2.8
23.5
3.5
-1.0
Pain
2.9
2.6
13.9
3.0
-1.4
Derma
2.8
2.6
8.5
3.1
-7.4
Anti Diabetic
2.1
1.8
16.9
2.2
-3.9
Respiratory
Anti-Infectives
19%
Gastro
Intestinal
14%
Page 22
Ajanta Pharmaceuticals
Stock Performance
290
240
190
140
90
40
Chronic,
247, 49.5%
SubChronic, 57,
11.4%
Acute, 195,
39.1%
Oct-15
Dec-15
Feb-16
Apr-16
Jun-16
CNX Pharma
Ajanta
21 to 30
31 to 50
Others
15.6
Sep-16
Aug-16
Jul-16
7.1
10.0
10.2
11.4
Ajanta Pharma

0.5
0.51
0.5
0.51
0.5
0.51 0.50
0.50
0.49
0.48
0.48 0.48
0.460.46
0.46
0.45
0.4
0.4
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
0.4
Aug-15
7.0
13.1
4.9
7.6
7.3
7.6
9.0
12.8
10.5
6.9
(%)
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
10.4
14.3
6.5
5
11 to 20
10.0
10
12%
9.9
(%)
10.4
12.6
15
13%
10%
Dec-15
13.3
20
43%
12.6
10.2
22%
Nov-15
Sep-15
25
23.1Oct-15
0.5
Oct-16
Top 10
Aug-16
Ajanta Pharma
(| crore)
Brand
Therapy
Met Xl
Cardiac
4.2
4.0
7.0
4.4
-3.8
Melacare
Derma
3.1
2.8
10.4
3.2
-1.7
Atorfit Cv
Cardiac
3.6
2.8
25.8
3.1
13.7
Soft Drops
Ophthal
1.4
1.4
-4.2
1.3
5.1
Rosufit Cv
Cardiac
1.4
1.1
24.4
1.6
-11.1
Feburic
Pain
1.3
1.1
17.9
1.4
-6.1
Met Xl Am
Cardiac
1.1
0.9
19.8
1.2
-10.3
Rosutor Gold
Cardiac
1.0
0.7
45.0
0.9
3.4
Cinod
Cardiac
1.0
0.7
41.1
1.0
-0.6
Olopat
Ophthal
0.7
0.7
10.1
0.7
8.6
Pain
5%
Others
9%
Vitamins
5%
Derma
21%
Cardiac
36%
Ophthal
24%
(| crore)
Therapy
Sep' 16
Sep' 15
YoY (%)
Aug' 16
MoM (%)
Cardiac
15.9
13.4
18.7
16.2
-1.5
Ophthal
10.7
9.8
8.9
10.2
5.4
Derma
8.3
8.4
-1.0
8.9
-7.0
Vitamins
2.1
2.6
-20.6
2.2
-6.0
Pain
2.0
2.1
-1.6
2.2
-5.6
Gastro Intestinal
1.1
1.1
0.2
1.0
11.7
Neuro
1.0
0.9
16.4
1.0
8.7
Anti-Infectives
1.1
0.7
47.5
1.0
10.8
Anti Diabetic
0.8
0.2
380.7
0.8
3.4
Respiratory
0.3
0.3
-8.2
0.3
-2.3
Page 23
Alembic Pharmaceuticals
Stock Performance
Chronic
231.46,
18.8%
Acute,
860,
58.8%
200
180
160
140
120
100
80
60
40
SubChronic
214.35,
17.4%
Oct-15
Dec-15
Feb-16
Apr-16
CNX Pharma
Jun-16
Aug-16
Oct-16
Alembic Pharma
Sep-16
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
35
21 to 30
31 to 50
Others
12.6
11.2
15.6
18.0
10.2
11.4
7.0
9.0
11.3
4.9
7.3
8.1
12.8
13.7
10.4
13.3
5.6
5
11 to 20
6.0
10
12%
10.4
(%)
15
10%
10.0
19.0
20
13%
20.5
23.3
24.1
25
43%
Top 10
23.1
31.5
30
22%
Alembic Pharma
1.49 1.49 1.48

1.43
1.42
Jul-16
Jun-16
Apr-16
1.41
1.31 1.30 1.32
May-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
1.36
Aug-16
1.43 1.44
1.47
Sep-16
1.6
1.5
1.5
1.4
1.4
1.3
1.3
1.2
1.2
Sep-15
(%)
Alembic Pharma

Anti-Infectives
23%
Gynaecological
11%
Respiratory
13%
Gastro
Intestinal
14%
Brand
Therapy
Azithral
Anti-Infectives

13.8
12.6
Althrocin
Anti-Infectives
9.5
Roxid
Anti-Infectives
4.9
Gestofit
Gynaecological
Wikoryl
Respiratory
Ulgel
10.0
14.3
-3.6
9.0
5.2
8.9
6.7
5.8
-15.2
5.7
-14.7
4.8
4.2
11.9
5.1
-7.7
5.1
3.3
54.4
5.1
0.7
Gastro Intestinal
3.3
3.6
-7.6
3.4
-2.0
Rekool D
Gastro Intestinal
2.7
3.0
-9.0
2.9
-7.8
Richar
Gynaecological
2.4
1.9
26.9
2.7
-11.6
Glisen Mf
Anti Diabetic
2.3
2.1
8.3
2.3
1.9
Rekool
Gastro Intestinal
2.0
2.1
-4.0
2.1
-1.7
Other
25%
(| crore)
Cardiac
14%

Therapy
Anti-Infectives
Cardiac
Gastro Intestinal
Respiratory
Gynaecological
Vitamins
Anti Diabetic
Pain
Urology
Derma
Sep' 16
33.7
18.4
17.8
19.1
14.2
11.0
9.1
4.7
2.9
1.9
Sep' 15
32.9
15.7
17.9
16.1
12.2
8.4
6.9
4.7
2.3
2.8
(| crore)
YoY (%)
2.5
17.2
-0.4
18.8
16.8
30.1
31.0
1.1
25.4
-33.7
Aug' 16
34.5
18.8
18.7
19.4
14.9
11.0
9.0
5.1
3.1
2.3
MoM (%)
-2.4
-1.9
-4.7
-1.5
-4.7
-0.3
0.6
-7.7
-3.7
-17.8
Page 24
ICICIdirect.com coverage universe (Healthcare)

CMP
(|)
TP
(|)
Ajanta Pharma
AJAPHA 1942 1,780 Hold
17086.2
45.4
52.8
63.6
42.7
36.8
30.5
29.9
25.0
21.2
42.9
37.1
35.0
34.2
30.2
Apollo Hospitals
APOHOS 1332 1,440 Hold
18533.6
22.2
18.5
28.7
60.0
72.0
46.5
27.8
27.9
22.5
8.2
7.3
9.6
8.9
7.0
9.9
Aurobindo Pharma
AURPHA
Buy
48209.2
33.9
41.3
48.0
24.3
19.9
17.2
25.0
20.5
17.7
23.3
24.6
25.5
28.1
26.0
23.5
Alembic Pharma
ALEMPHA 681
Hold
12830.3
38.2
20.4
28.1
17.8
33.4
24.2
12.4
23.1
17.5
51.5
23.2
26.2
44.9
20.5
23.5
620
M Cap
(| Cr)
PE(x)
EV/EBITDA (x)
RoCE (%)
RoE (%)
FY17E FY18E FY16 FY17E FY18E FY16 FY17E FY18E FY16 FY17E FY18E
I-Direct
Code
824 1,055
Rating
EPS (|)
FY16 FY17E FY18E FY16
Company
28.2
Biocon
BIOCON
950 1,030
Buy
18996.0
22.5
33.3
38.4
42.2
28.5
24.7
11.5
8.7
7.0
9.1
13.1
14.8
11.1
14.7
15.0
Cadila Healthcare
Cipla
CADHEA
CIPLA
392
587
Buy
Hold
40135.8
47171.0
15.0
18.5
15.8
17.6
20.3
25.4
26.2
31.7
24.9
33.3
19.3
23.1
17.1
20.3
17.5
18.5
13.8
13.7
26.7
12.0
22.9
11.1
26.8
15.2
28.6
12.5
24.7
10.8
25.6
13.8
Divi's Laboratories
DIVLAB
1235 1,415
Buy
32785.4
41.8
45.1
54.5
29.5
27.4
22.7
24.7
21.8
18.1
30.7
29.2
29.8
25.9
23.3
23.4
Dr Reddy's Labs
DRREDD 2974 2,875 Hold
51736.0
142.1
86.5
143.5
20.9
34.4
20.7
13.2
17.6
11.8
17.3
10.9
17.8
20.7
11.4
16.3
Glenmark Pharma
GLEPHA
858 1,000
Buy
26025.8
32.2
41.4
49.8
26.7
20.7
17.2
17.8
14.9
12.1
16.2
18.7
20.6
21.2
21.7
20.9
Indoco Remedies
INDREM
313
Buy
2881.1
9.0
13.6
19.4
34.7
23.0
16.1
17.9
13.5
10.4
12.5
17.3
23.4
14.2
18.3
21.7
Ipca Laboratories
Jubilant Life Sciences
Lupin
405
510
365
IPCLAB
620
605
Buy
7821.3
10.0
21.9
30.2
61.9
28.4
20.5
23.0
14.5
11.5
5.7
11.5
14.4
5.5
11.0
13.5
VAMORG
648
635
Buy
10324.2
26.0
41.4
52.7
24.9
15.6
12.3
10.6
8.7
7.2
12.0
15.1
17.0
14.2
18.8
19.6
20.2
1464 1,890
Buy
66060.4
50.4
64.6
75.5
29.1
22.7
19.4
20.2
15.4
12.7
18.6
20.6
22.1
20.7
21.7
Natco Pharma
NATPHA
LUPIN
612
700
Buy
10663.8
8.9
11.6
13.8
68.8
52.8
44.4
41.7
36.0
30.2
16.0
17.3
18.0
11.9
13.7
14.3
Sun Pharma
SUNPHA
746
890
Buy
179459.6
23.4
29.9
35.5
31.8
25.0
21.0
20.9
16.8
14.2
18.6
20.7
21.2
18.0
19.3
19.2
550
Syngene International
SYNINT
504
Buy
10076.0
11.1
15.8
18.7
42.7
29.9
25.3
26.1
20.8
16.7
13.2
17.4
19.3
21.0
23.6
22.3
Torrent Pharma
TORPHA
1636 1,650
Buy
27678.5
107.8
68.0
74.9
15.2
24.1
21.8
10.5
16.6
15.6
46.7
28.5
27.5
53.8
27.0
24.3
UNILAB
290
Buy
2632.5
12.3
15.3
21.1
23.5
19.0
13.7
14.9
12.0
8.6
13.8
15.7
18.9
11.7
12.9
15.5
340
Exhibit 92: One year forward P/E of CNX Pharma vs. Sensex
45
40
35
30
25
x
20
15
10
5
CNX Pharma
Oct-16
Apr-16
Oct-15
Apr-15
Oct-14
Oct-13
Apr-14
Apr-13
Oct-12
Apr-12
Oct-11
Apr-11
Oct-10
Apr-10
Oct-09
Apr-09
Oct-08
Apr-08
Oct-07
Apr-07
Oct-06
Sensex
Source: Company, ICICIdirect.com Research
Page 25
RATING RATIONALE
ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns

ratings to its stocks according to their notional target price vs. current market price and then categorises them
as Strong Buy, Buy, Add, Reduce and Sell. The performance horizon is two years unless specified and the
notional target price is defined as the analysts' valuation for a stock.
Sector view:
Over weight compared to index
Equal weight compared to index
Under weight compared to index
Index here refers to BSE 500
Pankaj Pandey
Head Research
pankaj.pandey@icicisecurities.com
ICICIdirect.com Research Desk,

ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No. 7, MIDC,
Andheri (East)
Mumbai 400 093
research@icicidirect.com
Page 26
ANALYST CERTIFICATION
We /I, Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report
accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or
view(s) in this report.
Terms & conditions and other disclosures:

ICICI Securities Limited is a Sebi registered Research Analyst having registration no. INH000000990. ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia,
engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is Indias largest private sector bank and has its various
subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (associates), the details in respect of which are
available on www.icicibank.com.
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking
and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts
and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and
meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without
prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securitiesis is under no obligation to update or keep the information
current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended
temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this
company, or in certain other circumstances.
This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This
report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial
instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their
receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific
circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment
objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate
the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any
loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the
risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to
change without notice.
ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment
in the past twelve months.
ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in
respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.
ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned
in the report in the past twelve months.
ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation
or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any
material conflict of interest at the time of publication of this report.
It is confirmed that Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the
preceding twelve months.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the
publication of the research report.
Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject
company/companies mentioned in this report.
It is confirmed that Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance), Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.
We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution,
publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities
described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and
to observe such restriction.
Page 27

IDirect HealthCheck Oct16

Transféré par

Informations du document

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

IDirect HealthCheck Oct16

Transféré par

Droits d'auteur :

Formats disponibles

Monthly Update

October 17, 2016

India, EMs to support Q2FY17 besides US

Index Performance as on October 14, 2016

Market cap in | crore

On the regulatory front, Cipla has received an establishment inspection

In Q2FY17, the I-direct healthcare universe revenues are expected to grow

ICICI Securities Ltd. | Retail Equity Research

M&As, demergers, tie-ups and JVs

Syngene purchases assets from Strand Life Sciences

~100 Medicines removed from NPPA list

ICICI Securities Ltd. | Retail Equity Research

Lupin Pharma is recalling 3,192 bottles (319,200 tablets) of Escitalopram

ICICI Securities Ltd. | Retail Equity Research

Apollo, Italy's KOS group launch medical rehabilitation hospital

ICICI Securities Ltd. | Retail Equity Research

Exhibit 2: Patent litigations (12 months)

Source: Bloomberg, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Therapy wise performance (| crore)

The Indian pharmaceutical market (IPM) grew 12.6% YoY to | 9792

Exhibit 3: Domestic formulations - growth trend

Top brands in Indian pharma market

Indian Pharma Market

Source: AIOCD data base, ICICIdirect.com Research

Source: AIOCD data base ; As per AIOCD MAT Sep 2016

Exhibit 4: Companies growth in domestic market in September, 2016

Industry acute to chronic therapy ratio percentage

Sep' 15 Gr. (%)

IPM grows 12.6% in September

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Therapy wise performance (| crore)

The Indian pharmaceutical market (IPM) grew 12.8% YoY to | 28641

Exhibit 5: Domestic formulations - quarterly growth trend

IPM grows 12.8% in Q2FY17

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 6: Company wise growth trends in Q2FY17

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Acute : Chronic contribution (| cr; MAT Sep16)

Source: NSE, ICICIdirect.com Research

Indian Pharma Market

Brands contribution to domestic sales (MAT Sep16)

Exhibit 7: Company growth vis--vis Indian pharma market growth

Sun Pharmaceutical Industries

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 8: Market share in Indian formulations market

Exhibit 9: Top 10 brands performance

Sep' 16 Sep' 15 Var. (%) Aug' 16 Var. (%)

8.9 8.8 9.0 8.8 8.9 8.8 8.7

Sun Pharmaceutical Industries

Source: AIOCD data base, ICICIdirect.com Research * Included Ranbaxys sales

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 10: Contribution of therapies to domestic sales (MAT Sep16)

Exhibit 11: Therapy wise performance

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Source: AIOCD data base, ICICIdirect.com Research

Acute : Chronic contribution (| cr; MAT Sep16)

Exhibit 14: Top 10 brands performance

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 13: Market share in Indian formulations market